Inactive Instrument

Other languages Keryx Biopharmaceuticals

Equities

Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS Enter into License Agreement	22-12-28
Keryx Biopharmaceuticals, Inc. Provides Preliminary Revenue Results for the First Quarter 2018	18-04-30
Keryx Biopharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Revises Revenue Guidance for the Full Year 2017	17-07-27
Keryx Biopharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2017; Provides Auryxia Net U.S. Product Sales Guidance for the Full Year of Fiscal 2017	17-05-04
Keryx Biopharmaceuticals, Inc. Announces Unaudited Preliminary Financial Results for the Fourth Quarter and Year Ended December 31, 2016	17-01-08
Accenture : Les valeurs à suivre sur les marchés américains	15-09-24
L'Agence européenne des médicaments rend un avis positif pour le Praluent de Sanofi	15-07-24

No results for this search